Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?

被引：2
|
作者：
Fabi, A [1 ]
Ferretti, G [1 ]
Salesi, N [1 ]
Papaldo, P [1 ]
Carlini, P [1 ]
Ciccarese, M [1 ]
Di Cocco, B [1 ]
Cecere, F [1 ]
Nardoni, C [1 ]
Felici, A [1 ]
Cognetti, F [1 ]
机构：
[1] Regina Elena Inst Canc Res, Div Med Oncol A, I-00144 Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷 / 03期
关键词：
D O I：
10.1093/annonc/mdi078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：516 / 517
页数：2
相关论文
共 50 条
  • [21] PHARMACOECONOMIC ANALYSIS OF PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS DOXORUBICIN IN PATIENTS WITH METASTATIC BREAST CANCER AT HIGH RISK OF CARDIAC EVENTS
    Krysanov, I
    Tiapkina, M.
    VALUE IN HEALTH, 2016, 19 (07) : A731 - A732
  • [22] Role of serum HER2 (sHER2) levels to predict acquisition of HER2 overexpression in patients with metastatic lesions of breast cancer with HER2-negative/unknown at the primary site
    Ribeiro, J. T. M. L.
    Ali, S. M.
    Correia, L.
    Luis, I. M. V. D.
    Matias, M.
    Amaral, T.
    Quintela, A. A. F. G.
    Leitzel, K.
    Lipton, A.
    Costa, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Influence of HER2 Overexpression on Response to Cetuximab in Patients with Metastatic Colorectal Cancer, Tehran, Iran
    Mozafari, Rambod
    Emami, Amir Hossein
    Nodehi, Sayyed Reza Safaee
    Shahi, Farhad
    Zebardast, Jayran
    Seyedalinaghi, SeyedAhmad
    Asadollahi-Amin, Ali
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2018, 6 (02): : 57 - 63
  • [24] Biweekly pegylated liposomal doxorubicin (Caelyx/Doxil) in heavily pretreated patients with metastatic breast cancer.
    Schmid, P
    Schulz, CO
    Dieing, A
    Lehenbauer-Dehm, S
    Flath, RA
    Sezer, O
    Possinger, K
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S204 - S204
  • [25] Liposomal doxorubicin in metastatic breast cancer
    Boer R.
    Breast Cancer Research, 2 (1)
  • [26] A multicentric observational trial with metastatic breast cancer (MBC) patients on pegylated liposomal doxorubicin (PLD) regimen
    Huober, J. B.
    Fett, W.
    Nusch, A.
    Neise, M.
    Schmidt, M.
    Wischnik, A.
    Gerhard, S.
    Goehler, T.
    Rost, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Weekly paclitaxel and pegylated liposomal doxorubicin in metastatic breast carcinoma
    Leonardi, V.
    Palmisano, V.
    Pepe, A.
    Usset, A.
    Savio, G.
    Laudani, A.
    Calabria, C.
    Tartaglia, L.
    Amari, P.
    Carruba, G.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 55 - 55
  • [28] Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial
    Elmar Stickeler
    Maximilian Klar
    Dirk Watermann
    Annette Geibel
    Martha Földi
    Annette Hasenburg
    Gerald Gitsch
    Breast Cancer Research and Treatment, 2009, 117 : 591 - 598
  • [29] Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial
    Stickeler, Elmar
    Klar, Maximilian
    Watermann, Dirk
    Geibel, Annette
    Foeldi, Martha
    Hasenburg, Annette
    Gitsch, Gerald
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (03) : 591 - 598
  • [30] MM-302 is more effective than PEGylated liposomal doxorubicin (PLD) at reducing pulmonary metastatic burden in breast cancer models expressing intermediate levels of HER2
    Dumont, Nancy
    Geretti, Eiena
    Leonard, Shannon Curtis
    Espelin, Christopher
    Gaddy, Daniel
    Hendriks, Bart
    Nielsen, Ulrik
    Wickham, Thomas
    CANCER RESEARCH, 2015, 75
12345